SCHEMBL6744743

SCHEMBL6744743

O=C1Cc2ccc(-c3ncco3)cc2N1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.48
AHR P35869 3/20 0.46
CMA1 P23946 2/20 0.46
CRBN Q96SW2 4/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
KDM1A O60341 1/20 0.45
EIF2AK2 P19525 1/20 0.45
CYP1A2 P05177 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
TDP2 O95551 2/20 0.40
BRD4 O60885 2/20 0.40
PDK2 Q15119 1/20 0.40
CREBBP Q92793 1/20 0.40
CHEK1 O14757 1/20 0.38
AURKA O14965 1/20 0.38
DAPK3 O43293 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6741494 0.76 CRBN (0.54) S1PR1AHRCMA1CRBNPDE3B
SCHEMBL29899582 0.75 CMA1 (0.55) AHRCMA1CRBNPDE3BPDE3A
SCHEMBL29899607 0.75 PDE3B (0.54) S1PR1AHRCMA1CRBNPDE3B
SCHEMBL23143561 0.75 PDE3B (0.54) AHRCMA1CRBNPDE3BPDE3A
SCHEMBL23143575 0.75 PDE3B (0.54) S1PR1AHRCMA1CRBNPDE3B
SCHEMBL23143591 0.75 CMA1 (0.55) AHRCMA1CRBNPDE3BPDE3A
SCHEMBL29899581 0.75 PDE3B (0.54) AHRCMA1CRBNPDE3BPDE3A
SCHEMBL29850050 0.75 PDE3B (0.76) AHRCMA1CRBNPDE3BPDE3A
SCHEMBL6744175 0.75 PDE3B (0.76) AHRCMA1CRBNPDE3BPDE3A
SCHEMBL5873706 0.74 TDP2 (0.70) AHRCMA1CRBNPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070088051-A1 INDOLINONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-19 US disclosed
US-6689806-B1 MODULATING PROTEIN KINASES AND RELATED SIGNAL TRANSDUCTION PATHWAYS SUGEN, INC. 2004-02-10 US disclosed
EP-1165513-A1 INDOLINONE COMPOUNDS AS KINASE INHIBITORS Sugen, Inc. (US) 2002-01-02 EP disclosed
WO-2000056709-A1 INDOLINONE COMPOUNDS AS KINASE INHIBITORS SUGEN, INC. (US) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088051-A1 INDOLINONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS MKI67, CCNT1, CCNA1 S1PR1 594/4885AHR 275/4885CMA1 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.